Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -5.26% is 75% above its 5-year average of -21.14%, near the high end of its 5-year range (-53.27%–6.95%).
177.18% below its 12-month average of -1.90%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 6.95%.
EBITDA MARGIN
-5.26%
EBITDA MARGIN AVG TTM
-1.90%
EBITDA MARGIN AVG 3Y
-13.93%
EBITDA MARGIN AVG 5Y
-21.14%
EBITDA MARGIN AVG 10Y
-10.57%
EBITDA MARGIN AVG 15Y
-2.63%
EBITDA MARGIN AVG 20Y
3.21%
CURRENT VS TTM AVG
-177.18%
CURRENT VS 3Y AVG
+62.23%
CURRENT VS 5Y AVG
+75.12%
CURRENT VS 10Y AVG
+50.24%
CURRENT VS 15Y AVG
-99.77%
CURRENT VS 20Y AVG
-263.70%
KORU Medical Systems, Inc.
Market Cap
$137.80M
EBITDA Margin
-5.26%
TTM Avg
-1.90%
3Y Avg
-13.93%
5Y Avg
-21.14%
Market Cap
$136.67M
EBITDA Margin
-410.84%
TTM Avg
-410.84%
3Y Avg
-410.84%
5Y Avg
-410.84%
Market Cap
$136.57M
EBITDA Margin
-27.14%
TTM Avg
-20.66%
3Y Avg
-62.77%
5Y Avg
-50.13%
Market Cap
$139.04M
EBITDA Margin
-16238.30%
TTM Avg
-8929.91%
3Y Avg
-4730.54%
5Y Avg
-4730.54%
Market Cap
$139.47M
EBITDA Margin
-221.15%
TTM Avg
-221.15%
3Y Avg
-221.15%
5Y Avg
-221.15%
Market Cap
$139.84M
EBITDA Margin
-95.26%
TTM Avg
-233.98%
3Y Avg
-174.91%
5Y Avg
-167.88%
Market Cap
$143.10M
EBITDA Margin
-783.01%
TTM Avg
-1033.45%
3Y Avg
-1010.27%
5Y Avg
-3715.70%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| KORU Medical Systems, Inc. (KRMD) | $137.80M | -5.26% | -1.90% | -13.93% | -21.14% |
| Atrium Therapeutics, Inc. (RNA)vs › | $136.67M | -410.84% | -410.84% | -410.84% | -410.84% |
| Organigram Global Inc. (OGI)vs › | $136.57M | -27.14% | -20.66% | -62.77% | -50.13% |
| Immuneering Corporation (IMRX)vs › | $139.04M | -16238.30% | -8929.91% | -4730.54% | -4730.54% |
| Alpha Cognition Inc (ACOG)vs › | $139.47M | -221.15% | -221.15% | -221.15% | -221.15% |
| Sutro Biopharma, Inc. (STRO)vs › | $139.84M | -95.26% | -233.98% | -174.91% | -167.88% |
| Freenome, Inc. (FRNM)vs › | $133.45M | N/A | N/A | N/A | N/A |
| Nyxoah S.A. (NYXH)vs › | $143.10M | -783.01% | -1033.45% | -1010.27% | -3715.70% |
| LifeMD, Inc. (LFMD)vs › | $132.03M | -0.19% | -1.66% | -11.02% | -42.72% |
| Protara Therapeutics, Inc. (TARA)vs › | $143.60M | -256.11% | -256.11% | -256.11% | -256.11% |
Gross Margin
62.0%
EBITDA Margin
-5.3%
Operating Margin
-3.7%
Net Margin
-4.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 6.95% |
| 2026-03-31 | -5.67% |
| 2025-12-31 | -3.38% |
| 2025-09-30 | -6.38% |
| 2025-06-30 | -1.01% |
| 2025-03-31 | -10.67% |
| 2024-12-31 | -16.90% |
| 2024-09-30 | -18.04% |
| 2024-06-30 | -11.56% |
| 2024-03-31 | -21.10% |
| 2023-12-31 | -27.40% |
| 2023-09-30 | -22.49% |
| 2023-06-30 | -43.42% |
| 2023-03-31 | -38.47% |
| 2022-12-31 | -31.64% |
| 2022-09-30 | -17.59% |
| 2022-06-30 | -53.27% |
| 2022-03-31 | -48.32% |
| 2021-12-31 | -30.81% |
| 2021-09-30 | -19.97% |
| 2021-06-30 | -22.84% |
| 2021-03-31 | -38.63% |
| 2020-12-31 | -25.72% |
| 2020-09-30 | 7.80% |
| 2020-06-30 | -12.16% |
| 2020-03-31 | 10.59% |
| 2019-12-31 | -1.16% |
| 2019-09-30 | 13.71% |
| 2019-06-30 | 2.28% |
| 2019-03-31 | -0.63% |
| 2018-12-31 | -8.33% |
| 2018-09-30 | 12.34% |
| 2018-06-30 | 15.39% |
| 2018-03-31 | 14.27% |
| 2017-12-31 | 16.62% |
| 2017-09-30 | 12.21% |
| 2017-06-30 | 6.98% |
| 2017-02-28 | -2.08% |
| 2016-11-30 | -0.91% |
| 2016-08-31 | -1.44% |
| 2016-05-31 | -10.01% |
| 2016-02-29 | 16.06% |
| 2015-11-30 | 11.43% |
| 2015-08-31 | 18.22% |
| 2015-05-31 | -0.54% |
| 2015-02-28 | 15.50% |
| 2014-11-30 | 7.76% |
| 2014-08-31 | 15.57% |
| 2014-05-31 | 11.41% |
| 2014-02-28 | 21.59% |
| 2013-11-30 | 13.70% |
| 2013-08-31 | 9.62% |
| 2013-05-31 | 9.59% |
| 2013-02-28 | 17.17% |
| 2012-11-30 | 6.70% |
| 2012-08-31 | 29.97% |
| 2012-05-31 | 10.70% |
| 2012-02-29 | 28.66% |
| 2011-11-30 | 16.87% |
| 2011-08-31 | 14.89% |
| 2011-05-31 | 23.71% |
| 2011-02-28 | 37.89% |
| 2010-11-30 | 24.44% |
| 2010-08-31 | 18.04% |
| 2010-05-31 | 15.42% |
| 2010-02-28 | 30.08% |
| 2009-11-30 | 13.77% |
| 2009-08-31 | 22.17% |
| 2009-05-31 | 14.36% |
| 2009-02-28 | 23.61% |
| 2008-11-30 | 25.73% |
| 2008-08-31 | 34.19% |
| 2008-05-31 | 13.51% |
| 2008-02-29 | 22.03% |
| 2007-11-30 | 15.62% |
| 2007-08-31 | 14.16% |
| 2007-05-31 | -19.49% |
| 2007-02-28 | 11.50% |
| 2006-11-30 | 9.25% |
| 2006-08-31 | 8.55% |
| 2006-05-31 | -28.35% |
| 2006-02-28 | -22.05% |
| 2005-11-30 | 21.05% |
| 2005-08-31 | -0.96% |
| 2005-05-31 | -28.68% |
| 2005-02-28 | -44.09% |
| 2004-11-30 | -27.58% |
| 2004-08-31 | -17.37% |
| 2004-05-31 | 6.51% |
| 2004-02-29 | -22.14% |
| 2003-11-30 | -12.17% |
| 2003-08-31 | -11.59% |
| 2003-05-31 | 0.06% |
| 2003-02-28 | -34.43% |
| 2002-11-30 | -4.08% |
| 2002-08-31 | 1.77% |
